Newsletter | July 8, 2026

07.08.26 -- Why The Next Era Of siRNA Belongs In Cardiology

SPONSOR

RNA Leaders USA is the go-to event for advancing RNA therapeutics. Connect with leading experts, explore new ideas, and gain practical insights into the latest RNA developments. Whether you're driving innovation or looking to stay ahead, this event is not to be missed. Join the conversation shaping the future of RNA!

FEATURED EDITORIAL

Targeting The Uncharted Heart: Why Next Era siRNA Belongs In Cardiology

By Anna Rose Welch, Advancing RNA

During our conversation, Gallagher walked me through what’s keeping her up at night as she leads the company and its first siRNA candidate toward an IND, elaborating on the role RNA can play in cardiomyopathies and identifying unique challenges of developing RNA medicines.

The "Short-Mer" Advantage: The Quality Gains Of siRNA Enzymatic Ligation

By Advancing RNA

Is enzymatic ligation merely a "volume play"? In this segment, Advancing RNA Live speakers Claire McCleod and Jill Caswell challenge this belief, explaining the extent at which this paradigm shift also unlocks higher siRNA purity.

From Exosomes To Nanodrugs: Advancing Therapy Delivery For CNS Repair

A conversation with Lior Shaltiel, Ph.D., CEO and director, NurExone Biologic

Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.

Scaling RNA Therapies: Purification, LNP Formulation, And GMP Manufacture

By Robert Dream, HDR Company LLC

Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.

INDUSTRY INSIGHTS

Unmatched Beginnings For Late-Phase Success

E-Book | Aldevron

Early research choices shape outcomes. Focusing on reproducibility, scalability, regulatory fit, and supply stability early cuts risk, prevents delays, and supports smoother development progress.

Success For mRNA: A Guide To Enhance Stability, Delivery, And Efficacy,

Article | By Conner Feldman, MilliporeSigma

RNA offers exciting potential for vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing persist.

The Sleek Science Of Ion Pair Reversed Phase Oligonucleotide Analysis

Article | KNAUER

Balance hydrophobic and ionic interactions to perfect oligonucleotide separation. See how selecting the correct cationic pairing agent maximizes retention and ensures mass spec alignment.

The M.O. To Choosing A CDMO: Evaluate With Three Criteria

Article | Curia

Moving a molecule from the bench to the bedside is a complex operational challenge. Use these three foundational considerations to ensure your CDMO has the capabilities to scale your project.

Five Practical Considerations To Move From Concept To Clinic

Webinar | Cytiva

Advance targeted in vivo LNP programs by addressing crucial developmental pillars. Review five essential factors ranging from formulation and targeting to analytical readiness and scalability.

SPONSOR

Join Advancing RNA Live Chief Editor Anna Rose Welch and expert panelists on July 9 at 11 AM ET. for the live virtual event: The mRNA Therapeutics Regulatory Paradigm: A Closer Look. This discussion is free thanks to event sponsor Roche CustomBiotech. Can't join live? No problem. Register today and reserve your link for the On Demand connection.

SOLUTIONS

Speed, Precision, Impact: The CRO Revolutionizing Bioanalysis

Dash Bio

mRNA/LNP Development And Manufacturing Services

Lonza

Biologics Manufacturing

Recipharm Advanced Bio